Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arbutus Biopharma ( (ABUS) ) has provided an update.
Arbutus Biopharma has announced promising results from its first quarter of 2025, highlighting the functional cure of eight chronic hepatitis B patients through imdusiran combination therapy, including two patients who did not require interferon. The company’s oral PD-L1 inhibitor, AB-101, has shown high receptor occupancy and safety in early clinical trials. Additionally, Arbutus has strengthened its leadership team with the appointment of Andrew J. Sung as General Counsel, bringing extensive experience in life sciences deals. These developments underscore Arbutus’s strong position in the biopharmaceutical industry, with significant implications for its operations and stakeholders.
The most recent analyst rating on (ABUS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page.
Spark’s Take on ABUS Stock
According to Spark, TipRanks’ AI Analyst, ABUS is a Neutral.
Arbutus Biopharma’s overall stock score reflects substantial financial challenges, including declining revenues and negative cash flows, which are the most significant factors weighing down the score. Moderate technical indicators and a challenging valuation outlook further contribute to the subdued score. While promising HBV treatment data offers some optimism, executive turnover and legal disputes present additional risks, maintaining a cautious outlook for the company’s stock performance.
To see Spark’s full report on ABUS stock, click here.
More about Arbutus Biopharma
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is involved in developing therapies for chronic hepatitis B (cHBV) and other infectious diseases, with a market focus on innovative treatments that address significant unmet medical needs.
Average Trading Volume: 1,077,888
Technical Sentiment Signal: Hold
Current Market Cap: $641.5M
For a thorough assessment of ABUS stock, go to TipRanks’ Stock Analysis page.